What is the address of Dr. UMBRASIENÉ Neringa, pediater?

The registered office of Dr. UMBRASIENÉ Neringa, pediater is located at Menenstraat 342, 8560 Wevelgem.

Is Dr. UMBRASIENÉ Neringa, pediater still active?

Yes. According to the CBE (26 September 2026) Dr. UMBRASIENÉ Neringa, pediater is active, legal situation “Normale toestand”, started on 17 April 2019.

Is Dr. UMBRASIENÉ Neringa, pediater registered on Peppol?

Yes, Dr. UMBRASIENÉ Neringa, pediater is registered on the Peppol network with ID 0208:0725445974.

What is the enterprise number of Dr. UMBRASIENÉ Neringa, pediater?

The enterprise number of Dr. UMBRASIENÉ Neringa, pediater is BE0725445974.

When was Dr. UMBRASIENÉ Neringa, pediater founded?

Dr. UMBRASIENÉ Neringa, pediater was founded on 17 April 2019.

Who are the directors of Dr. UMBRASIENÉ Neringa, pediater?

According to the 2025 annual accounts, the directors of Dr. UMBRASIENÉ Neringa, pediater are: Neringa Umbrasiené.

Is Dr. UMBRASIENÉ Neringa, pediater a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 April 2019; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. UMBRASIENÉ Neringa, pediater make in 2025?

Dr. UMBRASIENÉ Neringa, pediater posted a profit after taxes of € 74,607 in financial year 2025.

What is the revenue of Dr. UMBRASIENÉ Neringa, pediater?

As a small company, Dr. UMBRASIENÉ Neringa, pediater is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 114,378.

Dr. UMBRASIENÉ Neringa, pediater (Private Limited)

Dossier Dr. UMBRASIENÉ Neringa, pediater, printed on 26 September 2026 from databakkes.be/en/0725445974/dr-umbrasiene-neringa-pediater. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 8 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Dr. UMBRASIENÉ Neringa, pediater from Wevelgem, company number BE0725445974, closed financial year 2025 with a result of € 74,607 after tax. For that financial year Dr. UMBRASIENÉ Neringa, pediater recorded a gross margin of € 114,378 and equity of € 18,778. Compared with financial year 2024, the result moved from € 63,277 to € 74,607. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on March 5, 2026.

What it is worth Healthy

€ 18,778

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 74,607

▲ 18% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 13,753

▼ 62% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 74,607 paid out

100 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 60,201

▼ 21% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 59,096

▼ 21% vs 2024

€ 16,117 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 1,611

▲ 8% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 14,625

▲ € 14,314 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 81,924 Gross margin 2022: € 81,924 First fiscal year in the series	€ 101,853 Gross margin 2023: € 101,853 ▲ 24% vs 2022 (€ 81,924) Favourable step	€ 96,152 Gross margin 2024: € 96,152 ▼ 6% vs 2023 (€ 101,853) Unfavourable step	€ 114,378 Gross margin 2025: € 114,378 ▲ 19% vs 2024 (€ 96,152) Favourable step	▲ 19%
Profit after taxes	€ 60,937 Profit after taxes 2022: € 60,937 First fiscal year in the series	€ 77,322 Profit after taxes 2023: € 77,322 ▲ 27% vs 2022 (€ 60,937) Favourable step	€ 63,277 Profit after taxes 2024: € 63,277 ▼ 18% vs 2023 (€ 77,322) Unfavourable step	€ 74,607 Profit after taxes 2025: € 74,607 ▲ 18% vs 2024 (€ 63,277) Favourable step	▲ 18%
Equity	€ 132,247 Equity 2022: € 132,247 First fiscal year in the series	€ 98,110 Equity 2023: € 98,110 ▼ 26% vs 2022 (€ 132,247) Unfavourable step	€ 18,778 Equity 2024: € 18,778 ▼ 81% vs 2023 (€ 98,110) Unfavourable step	€ 18,778 Equity 2025: € 18,778 Unchanged (€ 18,778) Unchanged
Total debts	€ 5,268 Total debts 2022: € 5,268 First fiscal year in the series	€ 75,036 Total debts 2023: € 75,036 ▲ € 69,767 vs 2022 (€ 5,268) Unfavourable step	€ 244,907 Total debts 2024: € 244,907 ▲ 226% vs 2023 (€ 75,036) Unfavourable step	€ 234,574 Total debts 2025: € 234,574 ▼ 4% vs 2024 (€ 244,907) Favourable step	▼ 4%
Cash	€ 18,924 Cash 2022: € 18,924 First fiscal year in the series	€ 22,836 Cash 2023: € 22,836 ▲ 21% vs 2022 (€ 18,924) Favourable step	€ 36,586 Cash 2024: € 36,586 ▲ 60% vs 2023 (€ 22,836) Favourable step	€ 13,753 Cash 2025: € 13,753 ▼ 62% vs 2024 (€ 36,586) Unfavourable step	▼ 62%
Retained profit	€ 119,847 Retained profit 2022: € 119,847 First fiscal year in the series	€ 79,510 Retained profit 2023: € 79,510 ▼ 34% vs 2022 (€ 119,847) Unfavourable step	€ 178 Retained profit 2024: € 178 ▼ € 79,332 vs 2023 (€ 79,510) Unfavourable step	€ 178 Retained profit 2025: € 178 Unchanged (€ 178) Unchanged
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 117,659 Dividend 2023: € 117,659 Unchanged (€ 0) Unchanged	€ 142,608 Dividend 2024: € 142,608 ▲ 21% vs 2023 (€ 117,659) Unchanged	€ 74,607 Dividend 2025: € 74,607 ▼ 48% vs 2024 (€ 142,608) Unchanged	▼ 48%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 16,733 Bank debt 2023: € 16,733 Unchanged (€ 0) Unfavourable step	€ 74,632 Bank debt 2024: € 74,632 ▲ € 57,899 vs 2023 (€ 16,733) Unfavourable step	€ 59,096 Bank debt 2025: € 59,096 ▼ 21% vs 2024 (€ 74,632) Favourable step	▼ 21%
Balance sheet total	€ 137,515 Balance sheet total 2022: € 137,515 First fiscal year in the series	€ 173,146 Balance sheet total 2023: € 173,146 ▲ 26% vs 2022 (€ 137,515) Unchanged	€ 263,685 Balance sheet total 2024: € 263,685 ▲ 52% vs 2023 (€ 173,146) Unchanged	€ 253,352 Balance sheet total 2025: € 253,352 ▼ 4% vs 2024 (€ 263,685) Unchanged	▼ 4%

Key figures of Dr. UMBRASIENÉ Neringa, pediater, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. UMBRASIENÉ Neringa, pediater?

What happened at Dr. UMBRASIENÉ Neringa, pediater in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Mar 5, 2026 New annual accounts for financial year 2025: profit of € 74,607 (▲ 18% vs 2024). Source: NBB ↗
Apr 17, 2019 New establishment in Wevelgem. KBO
Apr 17, 2019 Start of the company according to the CBE. KBO

In short

From € 60,937 profit in 2022 to € 74,607 profit in 2025.

Paid € 74,500 in corporate taxes since 2022.

Best year ever: 2023, with € 77,322 profit.

Paid out € 334,874 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. UMBRASIENÉ Neringa, pediater? We notify you, reason included.

Follow Dr. UMBRASIENÉ Neringa, pediater

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Neringa Umbrasiené

Dr. UMBRASIENÉ Neringa, pediater

De Brave Raaf

Behind Dr. UMBRASIENÉ Neringa, pediater is Neringa Umbrasiené. Neringa Umbrasiené is also behind De Brave Raaf.

See the full network in the app

Directors

According to the 2025 annual accounts

Neringa Umbrasiené

Director

Also active at: De Brave Raaf

Establishments

Establishment units

Physical locations of this company

Registered office

Menenstraat 342

8560 Wevelgem

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0725.445.974
VAT number: BE 0725.445.974
Registered office: Menenstraat 342, 8560 Wevelgem
Names & denominations: Dr. UMBRASIENÉ Neringa, pediater
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 17 April 2019
Peppol: Active · Active since 30 Oct 2023

View on CBE Public ↗ Annual accounts (NBB) ↗